Urological Problems in Men – The Promise of Photodynamic Diagnosis and Distal Tip Sensors for Improved Diagnosis and Management

Share Article

Urology has long been at the forefront of minimally invasive technologies for diagnosis and treatment of urinary tract disorders. The global recession has impacted the urological endoscope market however, with slower growth than had previously been expected. The world market for urological endoscopes is projected to reach just over $530 million by the end of 2011. The economic slowdown in traditionally strong markets such as the US has led to a dip in sales. Recovery and growth in the longer term will be driven by demand for high-tech devices offering superior imaging and durability.

A newly published report titled, Urological Endoscopes Markets Worldwide by Marketstrat Inc., highlights some of the most exciting technologies that are creating new growth in this field. These include:

1)    Flexible optics with a powerful light source built into light-weight, thin endoscopes improve comfort for the patient and procedural ease.

2)    The photodynamic diagnosis (PDD) system developed by Karl Storz that uses HexvixTM (Hexaminolevulinate) for blue light cystoscopy (developed by Photocure and marketed by GE Healthcare). The PDD system is pending FDA approval in the US, although Hexvix has been available in Europe for the last 5 years. A number of clinical studies indicate a significant improvement in detection of bladder cancer.

3)    Distal tip sensors and HDTV provide high resolution digital images. The ‘chip-on-the-tip’ technology refers to two types of sensors: CCD (charge coupled device) or CMOS (complementary metal oxide semiconductor). The CMOS chip is a miniature device provides digital, color images, while a CCD chip provides narrow band imaging (NBI) to better identify cancerous tissue. Further advances in this technology are expected to greatly improve sensitivity and specificity for diagnosis.

With endoscopy being a mainstay of many urological procedures, new technology is readily accepted and tested, setting a precedent for other surgical specialties. Demand for urological endoscopes will continue to grow worldwide to address the high rates of bladder cancer, kidney stones and benign prostatic hyperplasia (BPH), some of the most common disorders in men. Emerging clinical evidence indicates that aging and obesity are tied to increased risk of both BPH and kidney stones. Risk of BPH can more than triple in men who are very obese, according to the Johns Hopkins School of Medicine. Risk of kidney stones has also recently been shown to be triple in men who are obese. (Brian R. Matlaga, MD, et al Journal of Urology, 2010). Bladder cancer, another common urological disorder in men, is the sixth most common cancer in the US with high rates in all industrialized countries. Although related mortality rates are declining, there is an overall increase in the number of newly diagnosed cases.

Leading manufacturers of minimally invasive technologies are focusing on expanding applications and developing high-tech accessories such as PACS/RIS and integrated OR systems. Olympus, the undisputed leader in optical technology and integrated medical systems, expanded its reach into the medical endoscopy field with the acquisition of Gyrus ACMI. Karl Storz and Stryker are close rivals with competitive offerings. Marketstrat’s report discusses these and other significant players in the field of urological endoscopy.

For more details on this report please click here.

About Marketstrat, Inc.
Marketstrat assists companies with market, technology, and best practice strategies & intelligence, through a unique combination of published reports, solutions, and services. Our strengths include: a deep understanding of the medical devices value chain, state-of-the-art data collection tools, and robust research methodology.

Marketstrat® is a registered trademark of Marketstrat, Inc.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website